X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA GSK PHARMA NATCO PHARMA/
GSK PHARMA
 
P/E (TTM) x 36.0 61.1 58.9% View Chart
P/BV x 18.3 12.0 152.9% View Chart
Dividend Yield % 0.6 2.1 30.4%  

Financials

 NATCO PHARMA   GSK PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
GSK PHARMA
Mar-16
NATCO PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs8773,850 22.8%   
Low Rs4242,966 14.3%   
Sales per share (Unadj.) Rs223.4332.3 67.2%  
Earnings per share (Unadj.) Rs31.144.3 70.1%  
Cash flow per share (Unadj.) Rs40.347.2 85.3%  
Dividends per share (Unadj.) Rs5.0050.00 10.0%  
Dividend yield (eoy) %0.81.5 52.4%  
Book value per share (Unadj.) Rs219.5202.7 108.3%  
Shares outstanding (eoy) m33.0784.70 39.0%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.910.3 28.4%   
Avg P/E ratio x20.976.9 27.2%  
P/CF ratio (eoy) x16.172.2 22.4%  
Price / Book Value ratio x3.016.8 17.6%  
Dividend payout %16.1112.9 14.3%   
Avg Mkt Cap Rs m21,504288,643 7.4%   
No. of employees `000NA4.6 0.0%   
Total wages/salary Rs m1,1284,434 25.4%   
Avg. sales/employee Rs ThNM6,104.5-  
Avg. wages/employee Rs ThNM961.6-  
Avg. net profit/employee Rs ThNM813.7-  
INCOME DATA
Net Sales Rs m7,38928,148 26.3%  
Other income Rs m1671,218 13.7%   
Total revenues Rs m7,55629,366 25.7%   
Gross profit Rs m1,7934,774 37.6%  
Depreciation Rs m304248 122.7%   
Interest Rs m3660-   
Profit before tax Rs m1,2905,744 22.5%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m026 0.0%   
Tax Rs m3092,018 15.3%   
Profit after tax Rs m1,0273,752 27.4%  
Gross profit margin %24.317.0 143.1%  
Effective tax rate %23.935.1 68.1%   
Net profit margin %13.913.3 104.3%  
BALANCE SHEET DATA
Current assets Rs m3,68121,462 17.2%   
Current liabilities Rs m3,12310,536 29.6%   
Net working cap to sales %7.638.8 19.5%  
Current ratio x1.22.0 57.9%  
Inventory Days Days8968 132.3%  
Debtors Days Days5916 357.5%  
Net fixed assets Rs m7,6854,717 162.9%   
Share capital Rs m331847 39.0%   
"Free" reserves Rs m6,67016,308 40.9%   
Net worth Rs m7,25917,171 42.3%   
Long term debt Rs m95516 5,968.1%   
Total assets Rs m11,95730,620 39.1%  
Interest coverage x4.5NM-  
Debt to equity ratio x0.10 14,118.2%  
Sales to assets ratio x0.60.9 67.2%   
Return on assets %11.712.3 95.1%  
Return on equity %14.221.9 64.8%  
Return on capital %20.733.6 61.7%  
Exports to sales %39.40 276,931.3%   
Imports to sales %5.715.1 37.9%   
Exports (fob) Rs m2,9084 72,695.0%   
Imports (cif) Rs m4214,237 9.9%   
Fx inflow Rs m3,445519 663.9%   
Fx outflow Rs m7038,320 8.4%   
Net fx Rs m2,743-7,801 -35.2%   
CASH FLOW
From Operations Rs m1,4401,386 103.9%  
From Investments Rs m-1,0895,010 -21.7%  
From Financial Activity Rs m-353-6,383 5.5%  
Net Cashflow Rs m-112 -12.6%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 50.7 2.9%  
Indian inst/Mut Fund % 7.8 10.2 76.9%  
FIIs % 16.6 23.8 69.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 15.4 168.8%  
Shareholders   25,395 102,036 24.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Steady Despite North Korea Threat(RoundUp)

Global financial markets ended the week on a flat note despite North Korea once again threatening to test a hydrogen bomb in the Pacific Ocean.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 22, 2017 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS